Effect of glucocorticoid in the treatment of severe drug-induced liver injury

Wei YAN; Huifang HUANG

doi:10.3969/j.issn.1001-5256.2022.10.019

Volume 38 Issue 10

Oct. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(10): 2302-2307

PDF( 1781 KB)

Effect of glucocorticoid in the treatment of severe drug-induced liver injury

DOI: 10.3969/j.issn.1001-5256.2022.10.019

Wei YAN¹,
Huifang HUANG^{2
,
,
,}

1.
The First Clinical Medical College of Shanxi Medical University, Taiyuan 030001, China
2.
Department of Gastroenterology, The First Hospital of Shanxi Medical University, Taiyuan 030001, China

Research funding:

Natural Science Foundation of Shanxi Province (201901D111357)

More Information

Corresponding author: HUANG Huifang, shxhhf@126.com(ORCID: 0000-0001-8526-0976)
Received Date: 2022-07-30
Accepted Date: 2022-08-31
Published Date: 2022-10-20

Abstract

Abstract

Objective To investigate the therapeutic effect of glucocorticoid in patients with severe drug-induced liver injury (DILI). Methods A retrospective analysis was performed for the data of patients with severe DILI who were admitted to The First Hospital of Shanxi Medical University from January 2019 to September 2021, including demographic characteristics, drugs inducing liver injury, and clinical manifestations, and changes in liver function, treatment outcome, and adverse reactions were compared between the patients treated with glucocorticoid (glucocorticoid group) and those not treated with glucocorticoid (control group). The independent samples t-test or the Mann-Whitney U test was used for comparison of continuous data between two groups, and the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups. Results A total of 88 patients with DILI were included in analysis, among whom there were 33 male patients and 55 female patients, with a median age of 49 years, and there were 61 patients in the control group and 27 patients in the glucocorticoid group. Hepatocellular injury type was the main clinical type, and traditional Chinese medicine and dietary supplements were the most common drugs inducing liver injury. Main clinical manifestations included jaundice, nausea, and poor appetite, and 6 patients (6/88, 6.82%) progressed to grade 4 DILI, with 2 patients in the glucocorticoid group and 4 in the control group. The comparison of baseline characteristics showed that there were significant differences between the glucocorticoid group and the control group in aspartate aminotransferase, gamma-glutamyl transpeptidase (GGT), total bilirubin (TBil), and the proportion of patients with positive immune indices (all P < 0.05). On day 3 of treatment, there were significant differences between the two groups in the reduction rates of TBil, international normalized ratio (INR), and total bile acid (TBA) (all P < 0.05); on day 7 of treatment, there were significant differences between the two groups in the reduction rates of alanine aminotransferase, GGT, INR, and TBA (all P < 0.05). Compared with the control group, the glucocorticoid group had a significantly higher cumulative response rate on days 3 and 7 of treatment (day 3: 59.26% vs 29.51%, χ²=55.82, P=0.008; day 7: 81.48% vs 29.51%, χ²=64.27, P < 0.001). In the glucocorticoid group, the 2 patients with grade 4 DILI showed no response, while treatment response was observed in 93.75% of the patients who were treated with glucocorticoid due to the reduction in liver enzymes and the persistent increase (or a lack of significant reduction) in bilirubin after conventional liver-protecting treatment. Conclusion Traditional Chinese medicine and dietary supplements are the most common drugs inducing liver injury, and short-term use of glucocorticoids may bring benefits to the patients with grade 3 DILI who fail to achieve a satisfactory reduction in bilirubin after conventional treatment.
- Chemical and Drug Induced Liver Injury,
- Glucocorticoids,
- Therapeutics

FullText(HTML)

References(20)

References

[1]	Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of Gastroenterology, et al. Guideline for primary care of drug-induced liver injury (2019)[J]. Chin J Gen Pract, 2020, 19(10): 868-875. DOI: 10.3760/cma.j.cn114798-20200812-00900. 中华医学会, 中华医学会杂志社, 中华医学会消化病学分会, 等. 药物性肝损伤基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2020, 19(10): 868-875. DOI: 10.3760/cma.j.cn114798-20200812-00900.
[2]	DEVARBHAVI H, DIERKHISING R, KREMERS WK, et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality[J]. Am J Gastroenterol, 2010, 105(11): 2396-2404. DOI: 10.1038/ajg.2010.287.
[3]	HU PF, XIE WF. Corticosteroid therapy in drug-induced liver injury: Pros and cons[J]. J Dig Dis, 2019, 20(3): 122-126. DOI: 10.1111/1751-2980.12697.
[4]	Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002. 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
[5]	LI WT, YANG L, HE HL, et al. Application of glucocorticosteroid in drug induced liver injury[J]. Chin Hepatol, 2020, 25(7): 676-678. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN202007008.htm 李文庭, 杨亮, 何宏亮, 等. 药物性肝损伤糖皮质激素应用的时机与指征[J]. 肝脏, 2020, 25(7): 676-678. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN202007008.htm
[6]	SGRO C, CLINARD F, OUAZIR K, et al. Incidence of drug-induced hepatic injuries: a French population-based study[J]. Hepatology, 2002, 36(2): 451-455. DOI: 10.1053/jhep.2002.34857.
[7]	BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425. DOI: 10.1053/j.gastro.2013.02.006.
[8]	SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. DOI: 10.1053/j.gastro.2019.02.002.
[9]	NAVARRO VJ, KHAN I, BJÖRNSSON E, et al. Liver injury from herbal and dietary supplements[J]. Hepatology, 2017, 65(1): 363-373. DOI: 10.1002/hep.28813.
[10]	European Association for the Study of the Liver. EASL clinical practice guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261. DOI: 10.1016/j.jhep.2019.02.014.
[11]	MOHAMMAD I, STARSKAIA I, NAGY T, et al. Estrogen receptor α contributes to T cell-mediated autoimmune inflammation by promoting T cell activation and proliferation[J]. Sci Signal, 2018, 11(526): eaap9415. DOI: 10.1126/scisignal.aap9415.
[12]	ROBLES-DIAZ M, GARCIA-CORTES M, MEDINA-CALIZ I, et al. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity[J]. Liver Int, 2015, 35(11): 2474-2482. DOI: 10.1111/liv.12834.
[13]	LI X, XU H, GAO P. Increased red cell distribution width predicts severity of drug-induced liver injury: a retrospective study[J]. Sci Rep, 2021, 11(1): 773. DOI: 10.1038/s41598-020-80116-4.
[14]	YU YC, CHEN CW. Pathogenesis of drug-induced liver injury: Current understanding and future needs[J]. J Clin Hepatol, 2021, 37(11): 2515-2524. DOI: 10.3969/j.issn.1001-5256.2021.11.003. 于乐成, 陈成伟. 药物性肝损伤的发生机制: 当前认识和未来需求[J]. 临床肝胆病杂志, 2021, 37(11): 2515-2524. DOI: 10.3969/j.issn.1001-5256.2021.11.003.
[15]	FONTANA RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives[J]. Gastroenterology, 2014, 146(4): 914-928. DOI: 10.1053/j.gastro.2013.12.032.
[16]	PARK BK, LAVERTY H, SRIVASTAVA A, et al. Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity[J]. Chem Biol Interact, 2011, 192(1-2): 30-36. DOI: 10.1016/j.cbi.2010.09.011.
[17]	HU PF, WANG PQ, CHEN H, et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury[J]. J Dig Dis, 2016, 17(9): 618-627. DOI: 10.1111/1751-2980.12383.
[18]	BJÖRNSSON HK, GUDBJORNSSON B, BJÖRNSSON ES. Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment[J]. J Hepatol, 2022, 76(1): 86-92. DOI: 10.1016/j.jhep.2021.08.024.
[19]	KARKHANIS J, VERNA EC, CHANG MS, et al. Steroid use in acute liver failure[J]. Hepatology, 2014, 59(2): 612-21. DOI: 10.1002/hep.26678.
[20]	DONG JL, JIA L, YANG J, et al. Expression features of glucocorticoid receptor and its association with treatment outcome in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2020, 36(6): 1252-1257. DOI: 10.3969/j.issn.1001-5256.2020.06.013. 董金玲, 贾琳, 杨君, 等. HBV相关慢加急性肝衰竭患者糖皮质激素受体表达特征及其与疗效的关系[J]. 临床肝胆病杂志, 2020, 36(6): 1252-1257. DOI: 10.3969/j.issn.1001-5256.2020.06.013.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (412) PDF downloads(83)

Effect of glucocorticoid in the treatment of severe drug-induced liver injury

DOI: 10.3969/j.issn.1001-5256.2022.10.019

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Effect of glucocorticoid in the treatment of severe drug-induced liver injury

DOI: 10.3969/j.issn.1001-5256.2022.10.019

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content